Pluristem Therapeutics (NASDAQ:PSTI) Raised to “Hold” at Zacks Investment Research

Zacks Investment Research upgraded shares of Pluristem Therapeutics (NASDAQ:PSTI) from a sell rating to a hold rating in a research note released on Wednesday, Zacks.com reports.

According to Zacks, “PLURISTEM THERAPEUTICS INC. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from the human placenta, a non-controversial source, and not from embryonic stem cells. “

Separately, Maxim Group reissued a buy rating and set a $315.00 price objective (up previously from $305.00) on shares of Domino’s Pizza in a report on Wednesday, April 24th.

Shares of PSTI stock opened at $0.56 on Wednesday. Pluristem Therapeutics has a 1-year low of $0.50 and a 1-year high of $1.38. The firm’s 50-day moving average is $0.60.

Pluristem Therapeutics (NASDAQ:PSTI) last posted its quarterly earnings data on Monday, May 6th. The biotechnology company reported ($0.09) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.07) by ($0.02). As a group, equities analysts predict that Pluristem Therapeutics will post -0.31 earnings per share for the current fiscal year.

A number of hedge funds have recently modified their holdings of the stock. ARK Investment Management LLC boosted its holdings in shares of Pluristem Therapeutics by 12.0% in the first quarter. ARK Investment Management LLC now owns 3,793,249 shares of the biotechnology company’s stock worth $3,679,000 after buying an additional 406,155 shares during the period. Nikko Asset Management Americas Inc. acquired a new position in shares of Pluristem Therapeutics during the 1st quarter worth about $900,000. Sumitomo Mitsui Trust Holdings Inc. acquired a new position in shares of Pluristem Therapeutics during the 1st quarter worth about $881,000. Virtu Financial LLC grew its position in shares of Pluristem Therapeutics by 266.1% during the 1st quarter. Virtu Financial LLC now owns 85,104 shares of the biotechnology company’s stock worth $83,000 after buying an additional 61,858 shares during the period. Finally, Van ECK Associates Corp grew its position in shares of Pluristem Therapeutics by 38.7% during the 4th quarter. Van ECK Associates Corp now owns 50,443 shares of the biotechnology company’s stock worth $40,000 after buying an additional 14,087 shares during the period. 6.00% of the stock is owned by hedge funds and other institutional investors.

About Pluristem Therapeutics

Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.

Further Reading: Forex

Get a free copy of the Zacks research report on Pluristem Therapeutics (PSTI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.